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Abstract
Background: Rhodococcus equi (R.equi) is an acid fast, GRAM + coccobacillus, which is widespread in the soil and
causes pulmonary and extrapulmonary infections in immunocompromised people. In the context of HIV infection,
R.equi infection (rhodococcosis) is regarded as an opportunistic disease, and its outcome is influenced by highly
active antiretroviral therapy (HAART).
Case presentation: We report two cases of HIV-related rhodococcosis that disseminated despite suppressive
HAART and anti-rhodococcal treatment; in both cases there was no immunological recovery, with CD4+ cells count
below 200/μL. In the first case, pulmonary rhodococcosis presented 6 months after initiation of HAART, and was
followed by an extracerebral intracranial and a cerebral rhodococcal abscess 1 and 8 months, respectively, after
onset of pulmonary infection. The second case was characterized by a protracted course with spread of infection
to various organs, including subcutaneous tissue, skin, colon and other intra-abdominal tissues, and central nervous
system; the spread started 4 years after clinical resolution of a first pulmonary manifestation and progressed over a
period of 2 years.
Conclusions: Our report highlights the importance of an effective immune recovery, despite fully suppressive
HAART, along with anti-rhodococcal therapy, in order to clear rhodococcal infection.
Background
Rhodococcus equi (R.equi) is an acid fast, GRAM + coc-
cobacillus, which was first isolated from suppurative pul-
monary lesions in foals [1]. The first human case of R.
equi infection (rhodococcosis) was reported in 1967 in an
immunocompromised patient with pneumonia [2] and its
frequency has increased significantly during the last 20
years [3-5], especially in immunocompromised patients,
such as transplant recipients and HIV-infected patients
[6,7]. Rhodococcosis is a rare infection, the exact preva-
lence of which is not known. Until now, more than 200
cases have been reported worldwide [4,6].
I nt h em a j o r i t yo ft h ec a s e s ,R. equi is acquired by
inhalation or aerosols coming from the stool of infected
foals. Excavated pneumonia is the most frequent clinical
manifestation [8], although spreading of the infection to
other organs is common, particularly in the immuno-
c o m p r o m i s e ds u b j e c t s[ 9 - 1 5 ] .T h ed i a g n o s i sr e l i e so n
radiological examinations [16], isolation of R. equi in
blood, sputum and other body fluids [17], and histologi-
cal examination of tissue samples, which may reveal
typical necrotizing granulomatous lesions, also termed
as malakoplakia [18].
There is no standard treatment for rhodococcosis and
it usually consists of a combination of at least two anti-
biotics to which the agent is susceptible. These include
macrolides, rifampin, floroquinolones, aminoglycosides,
glycopeptides and carbapenems, although newer drugs,
such as tygecicline and linezolid have also successfully
been used [19-21]. The choice should be based on the
results of antibiogram and drugs be given intravenously
for at least 2 weeks, followed by prolonged oral suppres-
sive antibiotic treatment [4]. Surgical drainage of
abscesses or cavitary lesions may also be required [9].
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in immunocompromised patients, with the highest mor-
tality (50-60%) in HIV infection. The use of highly active
antiretroviral therapy (HAART), however, has dramati-
cally changed the prognosis in HIV-infected patients,
with reported survival rates of virtually 100% [9]. The
cellular immunity, in particular Th1 response, appears
indeed to play a prominent role in the containment of
R. equi infection [22].
We here report two cases of R. equi pneumonia in
HIV-infected patients that disseminated despite virologi-
cally suppressive HAART, without CD4+ cell counts
increase above 200/μL. These cases highlight the impor-
t a n c eo fa ne f f e c t i v ei m m u n er e c o v e r yi n d u c e db y
HAART, along with appropriate antibiotic therapy, in
order to clear rhodococcal infection. In addition, they
illustrate the wide spectrum of clinical manifestations
caused by R. equi and the potential of non conventional
radiological approaches, such as nuclear techniques, in
the diagnostic work-up and follow-up of R. equi lesions.
Case Presentation
Case report 1
In April 2002 a 49 year-old HIV-infected woman was
admitted to hospital for persistent fever above 38°C and
cough (Table 1). She had started HAART with didano-
sine, lamivudine and indinavir in October 2001,when
her CD4+ cells count was 118/μL, and 2 months later
had developed brain and brain stem vasculitis-like con-
trast-enhancing, white matter lesions, consistent with
immune reconstitution central nervous system (CNS)
manifestations, for which she did not receive any
treatment.
At the time of admission in April, CD4+ cell count
was 123/μL and HIV-RNA was undetectable. Chest X-
ray showed a nodular opacity in the left upper lobe and
R. equi was cultured in blood and sputum, leading to a
diagnosis of R.equi pneumonia. Intravenous treatment
with vancomycin, imipenem, ceftriaxone and ciprofloxa-
cin was started, along with oral prednisone (75 mg qd
for 8 days, then tapered in 20 days) for a concomitant,
likely HIV-related, severe thrombocytopenia. In May
2002, the patient presented with generalized seizures.
Brain magnetic resonance imaging (MRI) confirmed the
presence of the known vasculitis-like lesions, still con-
trast enhancing, but also showed an extracranial abscess,
which was surgically removed and from which R. equi
was cultured. Intravenous antibiotic treatment was con-
tinued for a total of 8 weeks, then the patient received
oral ciprofloxacin and chlarithromycin for the following
15 weeks. In July 2002 patient’s respiratory symptoms
resolved, CD4+ cells count was 161/μLa n dH I VR N A
10,800 c/ml (patient had discontinued therapy in May
because of diarrhoea and resumed same HAART in
June), chest X-ray and CT scan showed complete
regression of the lung nodules. Because of new onset of
cognitive symptoms, and persistence of the contrast-
enhancing vasculitis-like brain lesions, oral prednisone
was started at 1 mg/Kg and gradually tapered for a total
of five months.
In December 2002, about 20 weeks after interruption
of anti-rhodococcal treatment, patient developed aniso-
coria, right hemiparesis, hypoaesthesia, hypopallaesthe-
sia, and dysmetria. At MRI, the known white matter
lesions were still present but no longer contrast enhan-
cing (Figure 1a), however, the exam showed two new
contrast-enhancing nodular lesions, surrounded by
oedema (Figure 1b, c). Cerebrospinal fluid (CSF) exami-
nation was unremarkable, no bacteria, mycobacteria and
fungi were cultured, cryptococcal antigen and Epstein-
Barr virus DNA were undetectable. Antitoxoplasmic
treatment was given empirically for 3 weeks, without
improvement of clinical conditions, and followed by
enlargement of the nodular lesions at MRI (Figure 1d-f).
Table 1 Summary of main clinical, laboratory and imaging findings from patient 1
Onset of
symptoms
(date)
Presenting symptoms Site of R. equi infection
(diagnostic technique)
CD 4 +
cells, HIV-1
RNA (VL)
HAART Treatment Duration
April 2002 fever, cough lung (culture of sputum, chest
X-ray). disseminated infection
(blood culture)
123 cells/μl,
VL < 50
copies/ml
didanosine,
lamivudine,
indinavir
induction (i.v.):
vancomycin 500 mg q6h
imipenem 500 mg q6h
ceftriaxone 2 g qd
ciprofloxacin 400 mg bid
maintanance (p.o.):
ciprofloxacin 500 mg bid
induction: 8
weeks
maintanance:15
weeks
May 2002 seizures head (brain MRI, culture of
surgically removed brain
abscess)
didanosine,
lamivudine,
indinavir
surgery, antibiotic therapy
(see above)
December
2002
anisocoria, right hemiparesis,
hypoaesthesia,
hypoallaesthesia, dysmetria
CNS (brain MRI) 143 cells/μl,
VL < 50
copies/ml
didanosine,
lamivudine,
indinavir
i.v.: ciprofloxacin 400 mg
tid vancomycin 500 mg
q6h ceftriaxone 2 g qd
3 weeks
Notes. VL viral load; i.v. intravenous; p.o. per os; CNS central nervous system; MRI magnetic resonance imaging
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Page 2 of 8In the suspect of brain rhodococcosis, intravenous treat-
ment with ciprofloxacin, vancomycin and ceftriaxone
was given for 3 weeks, together with oral prednisone,
followed by resolution of focal symptoms and improve-
ment of MRI lesions. During the following years, severe
neurological impairment with gait impairment persisted,
the patient developed progressive dementia and was
admitted to a long-term medical facility. Follow-up
brain MRIs documented the disappearance of the
abscesses, persistence of the vasculitis-like lesions and
development of cerebral atrophy. Patient changed
HAART for toxicity many times, and her immunovirolo-
gical situation remained stable. She did not develop rho-
dococcosis relapses or other opportunistic complications,
but died in December 2010 for ischemic cardiac events.
Case report 2
A 45 year old, HIV-infected woman, with a history of
breast carcinoma successfully treated with quadrantect-
omy and local radiotherapy, presented in May 2005 with
low-grade fever (below 38°C), cough and dyspnea (Table
2). She was off HAART since 2000, her CD4+ cells
count was 133/μl and HIV RNA 40,700 c/ml. She was
on cotrimoxazole as primary P. jiroveci pneumonia pro-
phylaxis. Chest X-ray and CT scan showed a 5 cm pul-
monary nodule in the upper right pulmonary lobe
(Figure 2a, b). R. equi was isolated from expectorate
and, based on the results of antibiogram, patient
received 2 weeks of intravenous rifampicin, levofloxacin
and azythromicin, followed by 8 weeks of oral levofloxa-
cin and azythromicin. HAART with lamivudine, tenofo-
vir and efavirenz was also started. Respiratory symptoms
resolved with progressive reduction of the pulmonary
lesions. In August, CD4+ cells count was 60/μl and HIV
RNA was undetectable (<50 c/ml). During the following
years, patient adherence to HAART remained poor until
she stopped treatment in 2008. Her CD4+ cells count
always remained below 200/μl, nevertheless, she neither
experience respiratory diseases nor any other HIV-
related manifestations.
In the summer of 2009, 4 years after R. equi pneumo-
nia, patient reported a weight loss of 10 Kg in 3 months
Figure 1 Central nervous system (CNS) immune reconstitution white matter lesions and R. equi brain abscesses by Magnetic
Resonance Imaging (MRI) (case report 1). a-c. Brain lesions at the onset of focal neurological symptoms. a. Axial FLAIR brain sequence
showing non specific asymmetric bilateral hyperintensity in the subcortical region, expression of immune recconstitution inflammatory reaction.
b. Axial FLAIR sequence showing abscessual lesion, surrounded by oedema, in the right temporal region. c. Gadolinium (Gd)-T1 sequence shows
the presence of nodular enhancement of the right temporal lesion. d-f. Evolution of brain lesions 1 month after onset of symptoms. d. Axial
FLAIR sequence shows the persistence of the non specific white matter hyperintensity; e. Axial FLAIR sequence shows an increase of lesion size
and oedema of the right temporal lesion; f. Gd-T1 sequence shows the evolution of contrast enhancement, now presenting as ring
enhancement, typical of an abscessual lesion.
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Page 3 of 8and low-grade fever, and noticed a subcutaneous, non
painful nodule in the right thigh. CD4+ cells count was
90/μL and HIV RNA 78,650 c/mL. An MRI of the tight
lesion was highly suggestive for a neoplastic lesion, with
necrosis and inflammation (Figure 2c, d), which
prompted a diagnostic work-up for tumor identification
and staging. A CT scan showed multiple abdominal
enlarged lymph nodes, and a 18-fluodeoxyglucose (FDG)
PET/CT scan showed increased metabolic activity of the
thigh lesion, colon and spleen (Figure 2e). However, a
needle biopsy of the thigh nodule demonstrated a non
necrotic granuloma, from which R.equi was cultured. A
colonoscopy showed a polipoid, stenotic lesion, which
histologically disclosed a picture of malakoplakia, with
the presence of microorganisms with morphology and
staining features consistent with R.equi.B a s e do nt h e
antibiogram, azythromicin, levofloxacin and ryfampicin
was started in September 2009. HAART with tenofovir,
emtricitabine and atazanavir was introduced 1 month
later, with rifampicin replaced by rifabutin, followed by
prompt virological response, but no significant CD4+
cells increase.
During the following weeks, patient’s conditions contin-
ued to worsen, with further weight loss, fever persistently
above 38°C, and onset of dyspnea, ascites and diarrhoea.
An abdominal MRI showed a 4 cm wide lesion of colon
and a 3 cm wide lesion in perisplenic peritoneum;
abdominal, celiac, para-hepatic and para-aortic enlarged
lymph nodes of 1-2 cm of diameter, peritoneal and
pleural effusion, while a chest high resolution CT scan
showed multiple lung consolidations. In November, anti-
biotic treatment was switched to imipenem and amikacin,
whilw HAART was modified with atazanavir replaced by
darunavir/ritonavir, followed by significant clinical
improvement and reduction of both dimension and meta-
bolic activity of the thigh lesion and abdominal lymph
nodes, as documented by conventional CT and 18-FDG
PET/CT scans. After 3 weeks, treatment was replaced by
oral levofloxacin and azythromicin. Remarkably, a new
gastric hypercaptation was noted at 18-FDG PET/CT
scan. In January 2010, the patient received extracorporeal
lithotripsy for nephrolithiasis, possibly consequent to
granulomatosis-associated hypercalciuria. At this time
there was no longer evidence of the thigh lesion.
Table 2 Summary of main clinical, laboratory and imaging findings from patient 2
Onset of
symptoms
(date)
Presenting
symptoms
Site of R. equi infection
(diagnostic technique)
CD 4 + cells,
HIV-1 RNA (VL)
HAART Treatment Duration
May 2005 fever, cough,
dyspnea
lung (culture of sputum, chest
X-ray, chest high resolution CT
scan)
133 cells/μl, VL:
40,700 copies/ml
lamivudine,
tenofovir,
efavirenz
induction (i.v.): rifampicin 600
mg qd, levofloxacin 500 mg qd,
azythromicin 500 mg qd
maintenance (p.o.): levofloxacin
500 mg qd azytromicin 500 mg
qd
induction: 2
weeks
maintenance:
8 weeks
September
2009
weight loss,
fever,
subcutaneous
nodule in the
right thigh
subcutaneous thigh tissue
(culture of granuloma, MRI,
needle aspirate); colon
(colonoscopy with biopsy)
90 cells/μl VL:
78,650 copies/ml
emtricitabine,
tenofovir,
atazanavir
azythromicin i.v. 500 mg qd,
levofloxacin i.v. 750 mg qd,
ryfampicin i.v. 600 mg qd,
switched to rifabutin p.o. 150
mg q48h at beginning of
HAART
8 weeks
November
2009
fever, ascites,
diarrhoea
colon, peritoneum, abdominal
lymph nodes, lung (total body
CT and PET scan)
59 cells/μl, VL: 778
copies/ml
emtricitabine,
tenofovir,
darunavir/r
induction (i.v.): imipenem 1 g
q6h amikacin 1 g qd
maintenance (p.o.): azythromicin
500 mg qd, levofloxacin 750 mg
qd
induction: 3
weeks
maintenance:
10 weeks
March 2010 fever,
abdominal
pain and
intestinal
bleeding
disseminated infection (blood
culture); colon (CT scan and
histological examination of
surgically removed colonic
tissue); lung (biopsy);
subcutaneous thigh tissue
(culture of needle aspirate, MRI);
skin.
62 cells/μlV L<
50 copies/ml
emtricitabine,
tenofovir,
darunavir/r
surgery induction (i.v.):
imipenem 500 mg q6h,
switched to ertapenem 1 g qd
after 7 weeks, levofloxacin 750
mg qd, vancomicin 500 mg bid,
azythromicin 500 mg qd
maintenance (p.o.): azythromicin
500 mg qd, rifabutin 150 mg
q48h
induction: 14
weeks
maintenance:
8 weeks
August
2010
headache CNS (brain CT scan and MRI) 74 cells/μlV L<
50 copies/ml
emtricitabine,
tenofovir,
darunavir/r
induction (i.v.): imipenem 500
mg q6h, amikacin 1 g qd
maintenance (i.v.): meropenem
1 g q8h, azythromicin 500 mg
qd, switched to ertapenem 1 g
qd after 10 weeks
induction: 3
weeks
maintenance:
10 weeks
Notes. VL viral load; i.v. intravenous; p.o. per os; CNS central nervous system; MRI magnetic resonance imaging
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Page 4 of 8In February 2010, after 10 weeks of anti-rhodococcal
oral therapy, patient self-suspended antibiotic and anti-
retroviral therapy for severe gastralgia. An esophago-
gastro-duodenoscopy (EGDS) showed esophageal candi-
diasis and the presence of a large stomach ulceration,
which was histologically proved to be a large B cell dif-
fuse lymphoma. CD4+ cells count was 62/μLa n dH I V -
RNA undetectable (<50 c/mL). Patient started proton
pump inhibitors and fluconazole.
In March 2010 the patient was admitted to Hospital
because of abdominal pain and intestinal bleeding
requiring blood transfusion. CT scan showed a solid
lesion in the right colon (Figure 2f), surrounded by mul-
tiple enlarged lymph nodes, with a radiologic appearance
of a colon cancer; colonscopy showed a large mass in
the proximal ascending colon, which was biopsied.
However, in the following days the patient developed
peritonitis and caecal perforation that required emer-
gency laparotomy and right hemicolectomy. Histological
examination of a 7 cm wide sessile, centrally excavated,
heteroplasia in the ascending colon and of peritoneal
lymphonodes showed malakoplakia of the intestine and
of perivisceral lymph nodes [23]. A similar histological
picture was disclosed by an echo-guided biopsy of a 2.5
Figure 2 R. equi lesions in disseminated infection (case report 2). a Chest radiograph (May 2005) shows a non specific subpleural opacity in
the right upper lobe without evidence of pleural effusion. b Contrast enhanced multidetector computed tomography (MDCT)(May 2005). A scan
at the level of the main bronchi demonstrates a subpleural focal consolidation in the right upper lobe. There is no evidence of
lymphoadenopathy or pleural effusion. c, d Contrast enhanced magnetic resonance imaging (MRI) of the right thigh (August 2009). The axial T2
sequence (c) and the axial T1 contrast enhanced sequence with fat suppression (ccGRE T1FS) (d) show an oval shaped enhancing mass in the
vastus medialis muscle with central area of necrosis and oedema of the surrounding tissue and muscle. e Positron emission tomography (PET)
and computed tomography (CT) images (August 2009) show focal increased fluodeoxyglucose (FDG) uptake in the upper lobe of the right lung
and in the spleen, which is larger than normal, a large area of increased uptake in the right lower abdomen consistent with colon localization,
and an irregular area of increased FDG uptake in the soft tissue of the right proximal thigh. f MDCT of the abdomen (March 2010). A scan
through the lower abdomen shows a large obstructing mass in the right colon with stranding of the pericolonic fat and several enlarged lymph
nodes. g Cutaneous nodular rhodococcal lesions (March 2010). h Brain axial T2 weighted sequence (August 2010) shows multiple (right
temporal, left mesial occipital, left temporoinsular) expansive oedematous lesions. All the lesions show central hypointensity and peripheral
hyperintensity. Oedema is also present in right occipital and anterior temporal lobes. i Brain axial T1 weighted sequence after Gd injection
(August 2010) shows enhancement of the two nodular lesions in right temporal region and in left occipitomesial lobe. Smooth cortical
enhancement is also seen in the left occipital lobe.
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Page 5 of 8cm wide lesion of the chest wall. Patient noticed also
the appearance of subcutaneous nodules on her face
(Figure 2g) and reappearance of the thigh lesion and R.
equi was isolated from both the thigh lesion and blood
samples. Based on antibiogram, patient was started
again on imipenem, levofloxacin and vancomicin;
intravenous azythromicin was added after 3 weeks. Van-
comicin was stopped after 4 weeks for severe thrombo-
cytopenia, imipenem replaced by ertapenem after
7 weeks and levofloxacin suspended after 8 weeks. After
a total of 14 weeks, intravenous treatment was substi-
tuted with oral azythromicin and rifabutin. In June
2010, patient’s conditions were improved, with disap-
pearance of the skin lesions, volume reduction of the
thigh lesion and lymph nodes at CT scans and no
abnormalities in lungs and brain. Multiple biopsies on a
control EGDS did not confirm the presence of gastric
lymphoma. Despite virological suppression, there was no
immunological improvement (74 CD4+ cells count/μL).
In August 2010, patient was admitted to hospital for
important headache, CT and MRI disclosed multiple
brain contrast-enhancing lesions, associated with cere-
bral oedema (Figure 2h, i). Intravenous imipenem and
amykacin were started together with mannitol and dexa-
methasone, followed by clinical improvement. Systemic
spread of rhodococcosis was excluded by a total body
CT scan. After 21 days treatment was changed to mero-
penem and azythromicin and, after 10 weeks, to ertape-
nem alone. MRI follow-up showed progressive reduction
of cerebral lesions, despite occurrence of seizures in
December 2010, for which antiepileptic therapy was
started.
Discussion and conclusions
Highly active antiretroviral therapy has impressively
reduced mortality and morbidity of opportunistic dis-
eases [24]. Nevertheless, these remain significant in
patients with low CD4+ cells count and during the first
months of therapy. This may either result from insuffi-
cient immunological recovery, or from the inflammatory
reaction to the opportunistic infection - the so called
immune reconstitution inflammatory syndrome (IRIS)-
[25,26].
None of the patients here described was indeed able
to increase the CD4+ cells count during the first months
of HAART, despite complete virological suppression,
and this was associated with the multi-organ spread of
rhodococcosis. Lack of immunological recovery, indeed,
is associated with enhanced risk of disease progression
and death, even in virologically suppressed patients [27].
Conversely, in the first patient, the immunological
recovery after CNS relapse was accompanied by a long
disease-free period.
The integrity of cellular immunity appears essential
for clearing R. equi infection [22]. During infection, R.
equi survives inside macrophages by inhibiting the for-
mation of the phagosome-lysosome and thereby its
degradation [28]. In vitro production of IFN-g and TNF-
a in response to stimulation with R. equi is significantly
impaired in AIDS patients compared to healthy subjects
[29], confirming the importance of adequate cellular,
and especially Th1 response for clearing the infection.
It is possible that the persistence of R. equi in macro-
phages also impairs the function of these cells, thus con-
tributing to maintain the immunodeficiency. Indeed,
lack of CD4+ T cell rise despite full virological suppres-
sion has also been observed in other HIV-associated
opportunistic infections, such as visceral leishmaniasis
[30], also characterized by the persistence of the para-
sites in macrophages [31]
In our first case, rhodococcal pneumonia occurred
6 months after the introduction of HAART, right after
a manifestation of CNS-IRIS, suggesting an immune
reconstitution associated event. Indeed, this case met
the definition criteria for “unmasking” IRIS, i.e.,
unmasking or paradoxical deterioration of an opportu-
nistic disease after introduction of an effective antiretro-
viral therapy [26,32]. A case of paradoxical worsening of
R. equi pneumonia following HAART initiation was also
recently described (i.e., paradoxycal IRIS)[33]. These
observations suggest that R. equi might be added to the
list of pathogens associated with IRIS. As for other
opportunistic infections, the first weeks after introduc-
tion of HAART are critical to this regard and patients
should be strictly monitored in order to early recognize
IRIS events. However, experience is still limited to
determine best timing of HAART introduction in the
context of rhodococcosis or use of antinflammatory
drugs if IRIS develops.
One important clinical issue in our second case was
the difficult diagnostic approach, which required inva-
sive techniques, such as needle biopsy and endoscopic
biopsy because of the difficult interpretation of the radi-
ological findings. In this setting the potential of “non-
conventional” techniques in the diagnostic work-up was
remarkable, with 18-FDG PET/CT that proved useful to
uncover silent localizations of the disease, such as the
colic and peritoneal lesions. This technique is a sensitive
tool not only in neoplastic diseases, but also in tubercu-
losis and invasive aspergillosis [34-36]. It was also
reported to be useful to disclose a rhodococcal localiza-
tion of the tongue [37], but it is not an established
means for diagnosis or monitoring of rhodococcosis.
Like in tuberculosis, high 18-FDG uptake in rhodococcal
lesions is likely related to high level of cell proliferation,
possibly in relation to the inflammatory process. It was
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Page 6 of 8challenging, in our second patient, to recognize R.equi
as the responsible of lesions, such as those at thigh,
colon and lung, the radiological appearance of which
resembled that of a neoplastic lesion, in a patient with
previous history of neoplasia and histological evidence
of gastric lymphoma.
While it is difficult to dissect the effect of individual
anti-rhodococcal agents in disseminated infection, it
appeared that a regimen containing carbapenems was
more effective in our second case than a combination of
rifampicin, levofloxacin and azythromicin, which had
previously been effective to cure pulmonary infection.
On the other hand, a combination of imipenem and
aminoglicosides, given for 3 weeks and followed by anti-
biotic maintenance therapy, although partially effective,
did not prevent subsequent progression of extrapulmon-
ary infection. Similarly, the subsequent 14 week course
with carbapenems, followed by oral antibiotic mainte-
nance, did not prevent later occurrence of CNS lesions.
In this regard, it is of note the dissemination of the
infection to the CNS in both of our cases, which
occurred in the first case months after apparent recov-
ery of R.equi pneumonia and, in the second case, despite
long-term induction and current maintenance therapy.
CNS involvement could have been due to spread of
infection to the CNS at the time of extra-cerebral dis-
ease, kept under control by systemic treatment, and
reactivated once antimicrobial treatment was inter-
rupted, such as in the first case, or switched to an oral
maintenance regimen, such as in the second case.
The cases here presented show that rhodococcosis
may disseminate to a number of tissues in HAART-trea-
ted immunological failing patients, and indicate that
long-term intravenous treatment might be required to
avoid relapses at distance, such in CNS, at least until a
sufficiently high CD4+ cell count, e.g., more than 200/
μL, is achieved. Achieving complete immune reconstitu-
tion by means of HAART remains the most important
weapon against rhodococcosis, in addition to combina-
tion antimicrobial treatment.
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